Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered at two Belgian hospitals;Caractérisation moléculaire de souches cliniques d'Escherichia coli producteurs d'AmpC isolées dans deux hôpitaux belges

Pathologie Biologie

Volumn 58, Issue 1, 2010, Pages 78-83

  Bogaerts, P ^a   Rodriguez Villalobos, H ^b   Bauraing, C ^a   Deplano, A ^b   Laurent, C ^a   Berhin, C ^a   Struelens, M J ^b   Glupczynski, Y ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

AmpC lactamases; Belgium; Cephalosporin resistance; Epidemiology; ESAC; Extended spectrum cephalosporinase; Rep PCR

Indexed keywords

BETA LACTAMASE AMPC; CEFEPIME; CEPHALOSPORINASE; EXTENDED SPECTRUM BETA LACTAMASE;

ALLELE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BELGIUM; CLONAL VARIATION; CONTROLLED STUDY; ESCHERICHIA COLI; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC SIMILARITY; MOLECULAR PHYLOGENY; NONHUMAN; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION;

BACTERIAL PROTEINS; BASE SEQUENCE; BELGIUM; BETA-LACTAMASES; CEPHALOSPORIN RESISTANCE; CHROMOSOMES, BACTERIAL; CLONE CELLS; CROSS INFECTION; DNA FINGERPRINTING; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HOSPITALS, UNIVERSITY; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMERASE CHAIN REACTION; R FACTORS; SEQUENCE ANALYSIS, DNA; SUBSTRATE SPECIFICITY;

EID: 77349116596     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2009.07.035     Document Type: Article

References (26)

1. Philippon A., Arlet G., Jacoby A.J. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002, 46:1-11.
2. Mammeri H., Nazic H., Naas T., Poirel L., Léotard S., Nordmann P. AmpC β-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 2004, 48:4050-4053.
3. Lee E.H., Nicolas M.H., Kitzis M.D., Pialoux G., Collatz E., Gutmann L. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother 1991, 35:1093-1098.
4. Poirel L., Heritier C., Spicq C., Nordmann P. In vivo acquisition of high-level resistance to Imipenem in Escherichia coli. J Clin Microbiol 2004, 42:3831-3833.
5. Mammeri H., Nordmann P., Berkani A., Eb F. Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol Lett 2008, 282:238-240.
6. Hanson N.D., Sanders C.C. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr Pharm Des 1999, 11:881-894.
7. Nelson E.C., Elisha B.G. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1999, 43:957-959.
8. Caroff N., Espaze E., Gautreau D., Richet H., Reynaud D. Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J Antimicrob Chemother 2000, 45:783-788.
9. Nordmann P., Mammeri H. Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol 2007, 2:297-307.
10. Kim J.Y., Jung H.I., An Y.J., Lee J.H., Kim S.J., Jeong S.H., et al. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol Microbiol 2006, 60:907-916.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 2008; 18th informational supplement. M100-S18. Clinical and Laboratory Standards Institute, Wayne, Pa.
12. Clermont O., Bonacorsi S., Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000, 10:4555-4558.
13. Bidet P., Metais A., Mahjoub-Messai F., Durand L., Dehem M., Aujard Y., et al. Detection and identification by PCR of a highly virulent phylogenetic subgroup among extraintestinal pathogenic Escherichia coli B2 strains. Appl Environ Microbiol 2007, 73:2373-2377.
14. Bogaerts P., Galimand M., Bauraing C., Deplano A., Vanhoof R., De Mendonca R., et al. Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium. J Antimicrob Chemother 2007, 59:459-464.
15. Perez-Perez F.J., Hanson N.D. Detection of plasmid-mediated AmpC ß-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002, 40:2153-2162.
16. CMY-2 among Salmonella and other Enterobacteriaceae. J Antimicrob Chemother 2006, 57:424-429.
17. Mammeri H., Poirel L., Fortineau N., Nordmann P. Naturally occurring extended-spectrum cephalosporinases in Escherichia coli. Antimicrob Agents Chemother 2006, 50:2573-2576.
18. Corvec S., Caroff N., Espaze E., Marraillac J., Reynaud A. -11 Mutation in the ampC promoter increasing resistance to beta-lactams in a clinical Escherichia coli strain. Antimicrob Agents Chemother 2002, 46:3265-3267.
19. Tracz D.M., Boyd D.A., Hizon R., Brice E., McGeer A., Ofner-Agostini M., et al. ampC gene expresssion in promoter mutants of cefoxitin-resistant Escherichia coli clinical isolates. FEMS Microbiol Lett 2007, 270:265-271.
20. Mammeri H., Eb F., Berkani A., Nordmann P. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital. J Antimicrob Chemother 2008, 61:498-503.
21. Corvec S., Prodhomme A., Giraudeau C., Dauvergne S., Reynaud A., Caroff N. Most Escherichia coli strains overproducing chromosomal AmpC β-lactamase belong to phylogenetic group A. J Antimicrob Chemother 2007, 60:872-876.
22. Haldorsen B., Aasnaes B., Dahl K.H., Hanssen A.M., Simonsen G.S., Walsh T.R., et al. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with acquired ISEcp1-like ampC element or hyperproduction of endogenous AmpC. J Antimicrob Chemother 2008, 62:694-702.
23. Mammeri H., Poirel L., Nordmann P. Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J Antimicrob Chemother 2007, 60:490-494.
24. Hee Lee S., Lee J.H., Heo M.J., Bae I.K., Jeong S.H., Cha S.S. Exact location of the region responsible for the extended substrate spectrum in Class C β-lactamases. Antimicrob Agents Chemother 2007, 51:3778-3779.
25. Vakulenko S.B., Golemi D., Geryk B., Suvorov M., Knox J.R., Mobashery S., et al. Mutational replacement of Leu-293 in Class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime. Antimicrob Agents Chemother 2002, 46:1966-1970.
26. Barnaud G., Benzerara Y., Gravisse J., Raskine L., Sanson-Lpors M.J., Labia R., et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in a Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother 2004, 48:1040-1042.